Making vascular access complications history
At the AVATAR group, we know that vascular access device insertion can be difficult and painful. After insertion, 25% to 50% fail due to infection, blockage, dislodgement or vessel damage. We conduct scientific work to improve hospital and homecare practices, test new products and promote global networks of vascular access researchers. We strive to eliminate ineffective practices and replace them with innovative solutions, providing patients with a better healthcare experience and saving healthcare providers millions of dollars.
Associate Professor Andrew Bulmer
Associate Professor Bulmer's research has two foci, the first of which includes revealing the importance of haem catabolism and bilirubin biology within inflammatory pathology, particularly atherosclerosis. Secondly, our group aims to reduce vasculitis and thrombotic events in patients enduring invasive vascular access devices/procedures with the AVATAR group.
Partners play an important role in developing reliable, practical and cost-effective products for the delivery of medical treatment and improving patient care. We engage with partners in a number of different ways.